Switzerland-based Galderma (SIX: GALD) disclosed that the US FDA has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for relabotulinumtoxinA (Relfydess), its ready-to-use liquid neuromodulator, delaying what would have been a significant commercial entry into the US injectable aesthetics market. The CRL relates solely to manufacturing observations and analytical method optimization identified during a Pre-License Inspection of Galderma’s manufacturing site; the FDA raised no deficiencies related to the safety or efficacy data supporting the application.
The FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing facility as part of its standard BLA review process. The agency identified observations during the PLI and also requested optimization of analytical methods. Galderma said it is implementing corrective and preventive actions to address the PLI observations and will seek further guidance through continued dialogue with the FDA. No new clinical studies were requested, and all clinical and safety-related components of the BLA were assessed without deficiencies. The nature of the manufacturing observations has not been disclosed in detail. Galderma stated that the findings do not affect approvals, launches, or regulatory reviews in markets outside the US.
RelabotulinumtoxinA is a complex-free, ready-to-use liquid botulinum toxin type A neuromodulator developed using Galderma’s proprietary PEARL Technology. Unlike conventional botulinum toxin products, it requires no reconstitution prior to injection, which Galderma positions as an operational and dosing consistency advantage for practitioners. The molecule acts by cleaving SNAP-25, a SNARE complex protein at the neuromuscular junction, thereby blocking acetylcholine release and inducing temporary muscle relaxation. The BLA covers aesthetic indications consistent with those approved in international markets.